{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:14:53Z","timestamp":1774908893879,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Venous thromboembolism (VTE) is a frequent complication in patients with cancer and causes considerable morbidity and mortality. The risk of VTE is higher in patients with pancreatic cancer and is often associated with treatment delays or interruptions. Recently, the ONKOTEV score was proposed as a VTE risk predictor model for patients with cancer, but its validation is still ongoing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study to determine the incidence of VTE and to evaluate the ONKOTEV score as a VTE predictive tool in a population of patients with pancreatic cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between February 2012 and May 2017, 165 patients were included in the study. The median age was 73\u2009years, 45.5% of patients were female, and 55.8% had stage IV disease. Fifty-one patients had a VTE (30.9%); 23.5% had pulmonary embolism, 25.5% had deep venous thrombosis, and 51.0% had visceral VTE (VsT). At a median follow-up time of 6.3 months, cumulative incidence of VTE was less than 10% for ONKOTEV scores 0 or 1 and approximately 40% and 70% for scores 2 and \u22653, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The high VTE incidence observed in this study is consistent with prior reports. Patients at high risk for VTE with no increase in hemorrhagic risk should be considered for primary thromboprophylaxis. The ONKOTEV score may stratify VTE risk in patients with pancreatic cancer, with ONKOTEV score \u22652 being associated with a higher VTE occurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0510","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T19:25:11Z","timestamp":1571772311000},"page":"e284-e290","source":"Crossref","is-referenced-by-count":25,"title":["ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer\u2014A Retrospective Analysis"],"prefix":"10.1093","volume":"25","author":[{"given":"Jo\u00e3o","family":"Godinho","sequence":"first","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Mafalda","family":"Casa-Nova","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Jo\u00e3o","family":"Moreira-Pinto","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Pedro","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Francisco","family":"Paralta Branco","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Lu\u00edsa","family":"Leal-Costa","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Ana","family":"Faria","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"F\u00e1bio","family":"Lopes","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Jos\u00e9 Alberto","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Passos-Coelho","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo, Loures, Portugal"},{"name":"Hospital da Luz, Lisboa, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"2021122510121143800_R1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"key":"2021122510121143800_R2","doi-asserted-by":"crossref","first-page":"16883","DOI":"10.18632\/oncotarget.24721","article-title":"Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"key":"2021122510121143800_R3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","article-title":"Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study","volume":"139","author":"Ashrani","year":"2016","journal-title":"Thromb Res"},{"issue":"suppl 3","key":"2021122510121143800_R4","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.21037\/cdt.2017.11.02","article-title":"Thrombosis in cancer patients: Etiology, incidence, and management","volume":"7","author":"Sheth","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2021122510121143800_R5","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1182\/blood.V122.21.4801.4801","article-title":"Venous thromboembolism (VTE) in patients with pancreatic cancer","volume":"122","author":"Yoon","year":"2013","journal-title":"Blood"},{"key":"2021122510121143800_R6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.6004\/jnccn.2012.0087","article-title":"Exocrine pancreas cancer and thromboembolic events: A systematic literature review","volume":"10","author":"Epstein","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122510121143800_R7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(04)01606-7","article-title":"Pancreatic cancer and thromboembolic disease","volume":"5","author":"Khorana","year":"2004","journal-title":"Lancet Oncol"},{"key":"2021122510121143800_R8","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000188","article-title":"Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: Review of the literature on current practice and emerging options","volume":"2","author":"Ay","year":"2017","journal-title":"ESMO Open"},{"key":"2021122510121143800_R9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1634\/theoncologist.12-11-1361","article-title":"The NCCN clinical practice guidelines on venous thromboembolic disease: Strategies for improving VTE prophylaxis in hospitalized cancer patients","volume":"12","author":"Khorana","year":"2007","journal-title":"The Oncologist"},{"key":"2021122510121143800_R10","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510121143800_R11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","article-title":"Guidance for the prevention and treatment of cancer-associated venous thromboembolism","volume":"41","author":"Khorana","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2021122510121143800_R12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: The ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"The Oncologist"},{"key":"2021122510121143800_R13","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2021122510121143800_R14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: Current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021122510121143800_R15","first-page":"566","article-title":"Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis","volume":"34","author":"Sproul","year":"1938","journal-title":"Am J Cancer"},{"key":"2021122510121143800_R16","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.26600","article-title":"Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer","volume":"118","author":"Epstein","year":"2012","journal-title":"Cancer"},{"key":"2021122510121143800_R17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb Haemost"},{"key":"2021122510121143800_R18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0399-8320(07)78352-5","article-title":"Risk of venous thrombosis in patients with pancreatic adenocarcinoma","volume":"31","author":"Mitry","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"2021122510121143800_R19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V118.21.674.674","article-title":"Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among U.S. cancer patients","volume":"118","author":"Khorana","year":"2011","journal-title":"Blood"},{"key":"2021122510121143800_R20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510121143800_R21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122510121143800_R22","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study","volume":"37","author":"Vadhan-Raj","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510121143800_R23","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2021122510121143800_R24","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"2021122510121143800_R25","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1055\/s-0038-1675577","article-title":"Cancer-associated thrombosis: Beyond clinical practice guidelines\u2014A multidisciplinary (SEMI-SEOM-SETH) expert consensus","volume":"02","author":"Pach\u00f3n","year":"2018","journal-title":"TH Open"},{"key":"2021122510121143800_R26","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.3747\/co.22.2653","article-title":"A population-based study of the epidemiology of pancreatic cancer: A brief report","volume":"22","author":"Raju","year":"2015","journal-title":"Curr Oncol"},{"key":"2021122510121143800_R27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021122510121143800_R28","article-title":"Characteristics of venous thromboembolism in pancreatic adenocarcinoma in East Asian ethnics: A large population-based observational study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine"},{"key":"2021122510121143800_R29","first-page":"4261","article-title":"Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients","volume":"30","author":"Shaib","year":"2010","journal-title":"Anticancer Res"},{"key":"2021122510121143800_R30","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/annonc\/mdm284","article-title":"Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients","volume":"18","author":"Mandal\u00e0","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122510121143800_R31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1499-3872(15)60397-6","article-title":"Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma","volume":"14","author":"Ouaissi","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2021122510121143800_R32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"2021122510121143800_R33","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122510121143800_R34","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clcc.2017.12.001","article-title":"Visceral thromboses in pancreas adenocarcinoma: Systematic review","volume":"17","author":"Hicks","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2021122510121143800_R35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clcc.2018.01.008","article-title":"Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma","volume":"17","author":"Mier-Hicks","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2021122510121143800_R36","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"2021122510121143800_R37","first-page":"350","article-title":"The clinical utility of the CA 19-9 tumor-associated antigen","volume":"85","author":"Steinberg","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2021122510121143800_R38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510121143800_R39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122510121143800_R40","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e284\/41920128\/oncolo_25_2_e284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e284\/41920128\/oncolo_25_2_e284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:12:38Z","timestamp":1640427158000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e284\/6443128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,22]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0510","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,22]]}}}